HERZLIYA, ISRAEL — January 29, 2026 — Leads & Copy — Regentis Biomaterials Ltd. (NYSE American:RGNT), a regenerative medicine company focused on tissue repair solutions, has expanded its U.S. clinical site network to support its Phase III study of GelrinC® for knee cartilage repair and future clinical programs.
The company is adding academic and clinical orthopedic centers to its network to accelerate patient enrollment and leverage orthopedic expertise.
“Building on our existing clinical collaborations, we are adding several new, highly regarded academic and clinical orthopedic centers to our network,” said Dr. Ehud Geller, Executive Chairman of Regentis.
GelrinC® is approved for knee cartilage repair in the European Union and is in a pivotal FDA trial for the same use, addressing a U.S. market of more than 470,000 potential cases annually.
The expanded clinical site network includes orthopedic surgeons and institutions with experience in cartilage repair, joint preservation, and sports medicine.
Participating clinical sites being added are:
NYU Langone Orthopedic & Sports Medicine, New York, NY, is known for surgical excellence. Dr. Laith Jazrawi brings academic leadership and clinical trial experience.
The Ohio State University Wexner Medical Center, Columbus, OH, has a high-volume orthopedic department. Dr. David Flanigan specializes in knee reconstruction and cartilage restoration.
University of Cincinnati Medical Center, Cincinnati, OH, integrates orthopedic care with research. Dr. Brian Grawe is known for his expertise in cartilage preservation.
Loyola Medicine Orthopedic, Maywood, IL, emphasizes innovation in joint preservation. Dr. John Miller contributes clinical insight in cartilage and meniscal pathology.
Tulane University School of Medicine – Orthopedics, New Orleans, LA, has a history of musculoskeletal research.
UNC Orthopedics, University of North Carolina, Chapel Hill, NC, focuses on clinical research. Prof. Joe Hart brings leadership in musculoskeletal research.
Rush University Medical Center, Chicago, IL, is recognized for orthopedic innovation. Dr. Adam Yanke is an expert in cartilage regeneration and knee preservation.
GelrinC®, Regentis’ lead product, is a cell-free hydrogel implant for treating painful knee cartilage injuries. It offers a ready-to-use procedure that provides patients with pain relief and functional improvement, according to clinical study results.
Regentis Biomaterials Ltd is focused on developing tissue repair solutions. Regentis’ Gelrin technology regenerates damaged tissue. GelrinC aims to address approximately 470,000 annual cases for cartilage knee repair in the U.S.
GelrinC is set to transform the cartilage repair market with off-the-shelf regenerative products, and new sites are expected to further accelerate patient enrollment, which surpassed 50% in Phase III study.
Source: Regentis Biomaterials
